Literature DB >> 26126592

Modelling MS: Chronic-Relapsing EAE in the NOD/Lt Mouse Strain.

Phuc T Dang1, Quyen Bui1, Claretta S D'Souza1, Jacqueline M Orian2.   

Abstract

Modelling complex disorders presents considerable challenges, and multiple sclerosis (MS) is no exception to this rule. The aetiology of MS is unknown, and its pathophysiology is poorly understood. Moreover, the last two decades have witnessed a dramatic revision of the long-held view of MS as an inflammatory demyelinating white matter disease. Instead, it is now regarded as a global central nervous system (CNS) disorder with a neurodegenerative component. Currently, there is no animal model recapitulating MS immunopathogenesis. Available models are based on autoimmune-mediated demyelination, denoted experimental autoimmune encephalomyelitis (EAE) or virally or chemically induced demyelination. Of these, the EAE model has been the most commonly used. It has been extensively improved since its first description and now exists as a number of variants, including genetically modified and humanized versions. Nonetheless, EAE is a distinct disease, and each variant models only certain facets of MS. Whilst the search for more refined MS models must continue, it is important to further explore where mechanisms underlying EAE provide proof-of-principle for those driving MS pathogenesis. EAE variants generated with the myelin component myelin oligodendrocyte glycoprotein (MOG) have emerged as the preferred ones, because in this particular variant disease is associated with both T- and B-cell effector mechanisms, together with demyelination. MOG-induced EAE in the non-obese diabetic (NOD) mouse strain exhibits a chronic-relapsing EAE clinical profile and high disease incidence. We describe the generation of this variant, its contribution to the understanding of MS immune and pathogenetic mechanisms and potential for evaluation of candidate therapies.

Entities:  

Keywords:  CNS demyelinating disease; Chronic-relapsing EAE; EAE; EAE variant; MOG; MS model; NOD/Lt mouse strain; Neurodegenerative disease; Neuroinflammation; Spatio-temporal lesion mapping

Mesh:

Substances:

Year:  2015        PMID: 26126592     DOI: 10.1007/7854_2015_378

Source DB:  PubMed          Journal:  Curr Top Behav Neurosci        ISSN: 1866-3370


  5 in total

1.  Sphingosine 1-phosphate receptor modulation suppresses pathogenic astrocyte activation and chronic progressive CNS inflammation.

Authors:  Veit Rothhammer; Jessica E Kenison; Emily Tjon; Maisa C Takenaka; Kalil Alves de Lima; Davis M Borucki; Chun-Cheih Chao; Annabel Wilz; Manon Blain; Luke Healy; Jack Antel; Francisco J Quintana
Journal:  Proc Natl Acad Sci U S A       Date:  2017-02-06       Impact factor: 11.205

Review 2.  Biological Sex As a Critical Variable in CD4+ Effector T Cell Function in Preclinical Models of Multiple Sclerosis.

Authors:  Muhammad Umair; Mohamed Reda Fazazi; Manu Rangachari
Journal:  Antioxid Redox Signal       Date:  2022-01-04       Impact factor: 7.468

3.  Autoimmune encephalomyelitis in NOD mice is not initially a progressive multiple sclerosis model.

Authors:  David Baker; Erik Nutma; Helen O'Shea; Anne Cooke; Jacqueline M Orian; Sandra Amor
Journal:  Ann Clin Transl Neurol       Date:  2019-07-15       Impact factor: 4.511

4.  Efficient Distribution of a Novel Zirconium-89 Labeled Anti-cd20 Antibody Following Subcutaneous and Intravenous Administration in Control and Experimental Autoimmune Encephalomyelitis-Variant Mice.

Authors:  Mary-Anne Migotto; Karine Mardon; Jacqueline Orian; Gisbert Weckbecker; Rainer Kneuer; Rajiv Bhalla; David C Reutens
Journal:  Front Immunol       Date:  2019-10-18       Impact factor: 7.561

5.  CSF1R signaling is a regulator of pathogenesis in progressive MS.

Authors:  Nellwyn Hagan; John L Kane; Deepak Grover; Lisa Woodworth; Charlotte Madore; Jacqueline Saleh; Jose Sancho; Jinyu Liu; Yi Li; Jonathan Proto; Matija Zelic; Amy Mahan; Michael Kothe; Andrew A Scholte; Maria Fitzgerald; Barbara Gisevius; Aiden Haghikia; Oleg Butovsky; Dimitry Ofengeim
Journal:  Cell Death Dis       Date:  2020-10-23       Impact factor: 8.469

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.